Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Zalcman

Showing results (11-20 of 113) with videos related to

Pageof 12
Sort By:
Revue Des Maladies Respiratoires|December 29, 2004
[Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting]J Madelaine, J Cadranel, G Zalcman
Revue Des Maladies Respiratoires|November 26, 2008
[Stage IV NSCLC. Biological treatments of lung cancer in 2008... and in the near future]E Bergot, G Levallet, G Zalcman
Revue Des Maladies Respiratoires|March 21, 2024
[The role of the pulmonologist in the therapeutic strategy for stage I bronchopulmonary cancers?]V Gounant, A Khalil, G Zalcman
Revue Des Maladies Respiratoires|February 22, 2008
[Mechanisms of action of targeted therapies... and mechanisms of resistance]E Bergot, N Richard, G Zalcman
Revue De Pneumologie Clinique|April 26, 2007
[New biological treatments for lung cancer]G Zalcman, N Richard, E Bergot
European Respiratory Review : an Official Journal of the European Respiratory Society|October 20, 2010
Update on nonsmall cell lung cancerG Zalcman, E Bergot, E Lechapt
Bulletin Du Cancer|January 1, 1995
[Genes and enzymes involved in the metabolism of carcinogens]J Trédaniel, G Zalcman, E Douriez
Revue Des Maladies Respiratoires|June 7, 2008
[Genetic susceptibility for lung cancer and nicotinic addiction: toward a molecular explanation?]E Bergot, G Levallet, G Zalcman
The Lancet. Oncology|October 14, 2016
Prophylactic radiotherapy to prevent procedure-tract metastasesG Zalcman, S Brosseau, A Scherpereel
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2015
Reply to the letter to the editor 'Flaws in the trial design of IFCT-0802' by Gyawali et alJ-L Pujol, F Morin, G Zalcman, et al.
Pageof 12

Showing results (11-20 of 113) with videos related to

Sort By:
Pageof 12
Revue Des Maladies Respiratoires|December 29, 2004
[Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting]J Madelaine, J Cadranel, G Zalcman
Revue Des Maladies Respiratoires|November 26, 2008
[Stage IV NSCLC. Biological treatments of lung cancer in 2008... and in the near future]E Bergot, G Levallet, G Zalcman
Revue Des Maladies Respiratoires|March 21, 2024
[The role of the pulmonologist in the therapeutic strategy for stage I bronchopulmonary cancers?]V Gounant, A Khalil, G Zalcman
Revue Des Maladies Respiratoires|February 22, 2008
[Mechanisms of action of targeted therapies... and mechanisms of resistance]E Bergot, N Richard, G Zalcman
Revue De Pneumologie Clinique|April 26, 2007
[New biological treatments for lung cancer]G Zalcman, N Richard, E Bergot
European Respiratory Review : an Official Journal of the European Respiratory Society|October 20, 2010
Update on nonsmall cell lung cancerG Zalcman, E Bergot, E Lechapt
Bulletin Du Cancer|January 1, 1995
[Genes and enzymes involved in the metabolism of carcinogens]J Trédaniel, G Zalcman, E Douriez
Revue Des Maladies Respiratoires|June 7, 2008
[Genetic susceptibility for lung cancer and nicotinic addiction: toward a molecular explanation?]E Bergot, G Levallet, G Zalcman
The Lancet. Oncology|October 14, 2016
Prophylactic radiotherapy to prevent procedure-tract metastasesG Zalcman, S Brosseau, A Scherpereel
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 9, 2015
Reply to the letter to the editor 'Flaws in the trial design of IFCT-0802' by Gyawali et alJ-L Pujol, F Morin, G Zalcman, et al.
Pageof 12